Cristina Gasparetto, MD, on Multiple Myeloma: Selinexor, Carfilzomib, and Dexamethasone in Carfilzomib-Nonrefractory Patients
EHA 2021 Virtual Congress
Cristina Gasparetto, MD, of Duke University, discusses findings from a study that suggests patients with heavily pretreated multiple myeloma benefit from weekly selinexor, carfilzomib, and dexamethasone, which was reported to be active, with an overall response rate of 78% and an overall progression-free survival of 23 months (Abstract S188).
The ASCO Post Staff
Arnon P. Kater, MD, PhD, of the University of Amsterdam, discusses a primary analysis of the phase III GLOW study, which, for the first time, compared the efficacy and safety of fixed-duration ibrutinib plus venetoclax with chlorambucil plus obinutuzumab for first-line treatment of older patients with chronic lymphocytic leukemia (LB1902).
The ASCO Post Staff
Claire Harrison, MD, of Guy’s and St. Thomas’ Hospital, discusses survival results from the JAKARTA and JAKARTA2 trials, which showed that fedratinib, an oral JAK2 inhibitor, significantly improved progression-free survival vs placebo as a first-line treatment for patients with myelofibrosis (Abstract S203).
The ASCO Post Staff
Keith W. Pratz, MD, of the University of Pennsylvania, discusses the outcomes of patients with acute myeloid leukemia who took part in the VIALE-A trial and were treated with venetoclax and azacitidine. The patients had achieved both composite complete remission and measurable residual disease of < 10-3 (Abstract S137).
The ASCO Post Staff
Ruben A. Mesa, MD, of UT Health San Antonio Cancer Center, discusses new findings on momelotinib, a potent JAK1, JAK2, and ACVR1 inhibitor with clinical activity against hallmark features of myelofibrosis such as anemia and splenomegaly. Results showed that transfusion independence was associated with improved overall survival in patients who had received momelotinib (Abstract S202).
The ASCO Post Staff
Philippe Moreau, MD, of University Hospital Hôtel-Dieu, discusses findings from the CASSIOPEIA trial, Part 1, on daratumumab maintenance vs observation in patients with newly diagnosed multiple myeloma who have been treated with bortezomib, thalidomide, and dexamethasone, with or without daratumumab, and autologous stem cell transplantation (Abstract S180).
